ArticleInvestigational new drugs2020

Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.

Shunsuke Kondo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.